Company Overview
Company Type: Private Company
Website: www.aceruspharma.com
Number of Employees: 14
Year Founded: 2008
Total Amount Raised (CAD mm)†: 123.10
Total Rounds of Funding**:9
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
4.2
Market Capitalization
2.3
TEV/Total Revenue
14.7x
EBITDA
(34.6)
Total Enterprise Value
61.3
TEV/EBITDA
NM
EBIT
(34.9)
Cash & ST Invst.
4.1
P/Diluted EPS Before Extra
NM
Net Income
(38.4)
Total Debt
63.1
Price/Tang BV
NM
Capital Expenditure
(0.2)
Total Assets
65.2
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Sep-30-2022 TEV and Market Cap are calculated using a close price as of Jan-18-2023

Key Professionals
Name
Title
Gudaitis, Edward 
President, CEO & Director
Manzoor, Naveed 
Interim Chief Financial Officer
Witty, Chris 
Investor Relations
Savard, Philippe 
Senior VP, General Counsel & Corporate Secretary
Damstra, Gavin 
Senior Vice President of International Commercial

Key Board Members
Name
Title
Ihnatowycz, Ian Orest
Chairman of the Board
Gudaitis, Edward 
President, CEO & Director
Herschkowitz, Samuel 
Vice Chairman
Cotton, Geoffrey David
Independent Director
Gregory, Stephen Robert
Independent Director
Chabursky, Borys 
Lead Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
7025 Langer Drive Suite 205 | Mississauga, ON | L5N 0E8 | Canada

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
First Generation Capital Inc.
Feb-19-2014
Majority
85.82 %
PIPE

Prior Investors
Aytu BioPharma, Inc. (NasdaqCM:AYTU), GE HFS Holdings, Inc., K2 & Associates Investment Management Inc., The K2 Principal Fund L.P., West Face Capital Inc., West Face Long Term Opportunities Global Master L.P


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Serenity Pharmaceuticals, LLC
Serenity Pharmaceuticals, LLC, a pharmaceutical company, engages in developing therapies for diseases associated with voiding disorders. It offers Noctiva, a desmopressin acetate nasal spray for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. The company was founded in 2006 and is based in Milford, Pennsylvania with an operation in Miami, Florida. Serenity Pharmaceuticals, LLC operates as a subsidiary of Acerus Pharmaceuticals Corporation.

United States and Canada
Pharmaceuticals
-
-
-
J5 Acquisition Corp.
As of July 14, 2011, J5 Acquisition Corp. was acquired by Acerus Pharmaceuticals Corporation, in a reverse merger transaction. Trimel Pharmaceuticals Corporation focuses on the redevelopment of known pharmaceutical compounds in order to improve their performance and merchantability by employing localized dosing technologies (LDT) that are designed to avoid first pass metabolism. It acquires three LDT platforms, and pursuing the development and application of these technologies to various high value pharmaceutical compounds. The company focuses on the therapeutic areas of allergy, asthma, and endocrinology. Trimel Pharmaceuticals Corporation is headquartered in Mississauga, Canada.

United States and Canada
Pharmaceuticals
-
0.00
0.00
Acerus Biopharma Inc.
Acerus Biopharma Inc., formerly known as Acerus Pharmaceuticals SRL, is headquartered in Barbados. The company operates as a subsidiary of Acerus Pharmaceuticals Corporation.

Latin America and Caribbean
-
-
-
-
Trimel BioPharma SRL
Trimel BioPharma SRL operates as a subsidiary of Acerus Pharmaceuticals Corporation 

Latin America and Caribbean
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-28-2022
Mar-07-2022
Merger/Acquisition
Buyer
Serenity Pharmaceuticals, LLC
Acerus Pharmaceuticals Corporation
Fein Family Enterprises, LLC,Rev5 Family Trust
41.38
Oct-19-2020
Nov-24-2020
Public Offering
Target
Acerus Pharmaceuticals Corporation


10.10
Feb-12-2020
Feb-21-2020
Private Placement
Target
Acerus Pharmaceuticals Corporation
First Generation Capital Inc.

18.11
Mar-29-2019
Mar-29-2019
Private Placement
Target
Acerus Pharmaceuticals Corporation
First Generation Capital Inc.

3.39
Jun-6-2018
Jun-28-2018
Public Offering
Target
Acerus Pharmaceuticals Corporation


4.99
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-21-2023
Delistings
Acerus Pharmaceuticals Common Shares to Be Deleted from OTC Equity
Feb-06-2023
Delistings
Acerus Pharmaceuticals to Delist from TSX on March 03, 2023
Jan-26-2023
Delistings
TSX Suspends Trading of Acerus Pharmaceuticals Common Shares to Expedite Delisting Review Process
Dec-26-2022
Executive/Board Changes - Other
Acerus Pharmaceuticals Corporation Announces Resignation of Scott Leckie from the Board of Directors
Dec-22-2022
Debt Financing Related
Acerus Pharmaceuticals Corporation and its Wholly-Owned Subsidiary, Acerus Pharmaceuticals USA, LLC Enter into USD 2 Million Secured Loan Agreement with First Generation Capital Inc

Competitors
Allergan plc, Antares Pharma, Inc., Bausch Health Companies Inc. (NYSE:BHC), BGP Pharma ULC, Cipher Pharmaceuticals Inc. (TSX:CPH), Clarus Therapeutics Holdings, Inc. (Out of Business), Eli Lilly and Company (NYSE:LLY), HLS Therapeutics Inc. (TSX:HLS), Nuvo Pharmaceuticals Inc., PendoPharm Inc., Pharmascience Inc., Purdue Pharma Inc., Sandoz International GmbH, Taro Pharmaceuticals Inc., Teva Pharmaceutical Industries Limited (NYSE:TEVA), Valeant Canada Ltd., Viatris Inc. (NasdaqGS:VTRS)

M&A Advisors
Sidley Austin LLP, Stikeman Elliott LLP, Torreya Capital, LLC


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Sidley Austin LLP, Stikeman Elliott LLP, Torreya Capital, LLC
Private Placement Advisors
Cormark Securities Inc., Stikeman Elliott LLP, Torreya Capital, LLC
Public Offering Advisors
PricewaterhouseCoopers LLP, Canada, Stikeman Elliott LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 08, 2023 01:31 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp - Strategic SWOT Analysis Review
Reports
138
GlobalData

Aug 23, 2023 06:48 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
60
S&P Global Compustat

Jul 06, 2023 03:18 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp 2023_07_06
Reports
15
GlobalData

Jun 22, 2023 03:22 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
60
GlobalData

Jun 08, 2023 05:05 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp - Strategic SWOT Analysis Review
Reports
142
S&P Global Compustat

Jun 01, 2023 04:04 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp 2023_06_01
Reports
15
S&P Global Compustat

May 04, 2023 03:40 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp 2023_05_04
Reports
15
S&P Global Compustat

Apr 06, 2023 03:55 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp 2023_04_06
Reports
15
GlobalData

Mar 20, 2023 05:49 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp (ASPCF.OTC) - Financial and Strategic SWOT Analysis Review
Reports
159
GlobalData

Mar 17, 2023 05:49 AM
Acerus Pharmaceuticals Corporation
Acerus Pharmaceuticals Corp (ASPCF.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
58



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
First Generation Capital Inc.
0
(6,882,515)
Gudaitis, Edward 
0
(79,482)
Gregory, Stephen Robert
0
(45,552)
Herschkowitz M.D., Samuel 
0
(2,500)
Chabursky BSc, Borys 
0
(2,437)
Savard, Philippe 
0
(358)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Avanafil, Elegant pH (Future), Elegant Vaginal Moisturizer (Future), Estrace, Licensing of TriVair Pulmonary Delivery Technology, Lidbree (Future), Natesto, Noctiva (Future), Noctiva Plus (Future), TBS-2 (Future), Tefina (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jul-10-2023
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
134 KB
Jul-10-2023
-
Acerus Pharmaceuticals Corporation
SEDAR
Material Change Report
107 KB
May-25-2023
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
128 KB
Mar-14-2023
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
144 KB
Jan-26-2023
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
164 KB
Dec-28-2022
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
156 KB
Dec-22-2022
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
192 KB
Nov-15-2022
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
245 KB
Nov-14-2022
Sep-30-2022
Acerus Pharmaceuticals Corporation
SEDAR
Interim Financial Statements
489 KB
Oct-03-2022
-
Acerus Pharmaceuticals Corporation
SEDAR
News Releases
151 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Herschkowitz M.D., Samuel  (Vice Chairman)
May-25-2022
New Common Stock
100
42,880
Open Market Acquisition
4.17
Multiple
Herschkowitz M.D., Samuel  (Vice Chairman)
May-20-2022
New Common Stock
200
938
Open Market Acquisition
9.09
Multiple
Herschkowitz M.D., Samuel  (Vice Chairman)
May-12-2022 - May-19-2022
New Common Stock
2,200
11,416
Open Market Acquisition
New
Multiple
-
May-19-2022
New Common Stock
100
497
Open Market Acquisition
-
Exchange Announcement
-
May-18-2022
New Common Stock
100
531
Open Market Acquisition
-
Exchange Announcement
-
May-12-2022
New Common Stock
2,000
10,388
Open Market Acquisition
-
Exchange Announcement
Motz, Robert M. (Former Chief Financial Officer)
May-11-2022
New Common Stock
500
2,388
Open Market Acquisition
24.93
Multiple
-
May-11-2022
New Common Stock
100
465
Open Market Acquisition
-
Exchange Announcement
-
May-11-2022
New Common Stock
200
951
Open Market Acquisition
-
Exchange Announcement
-
May-11-2022
New Common Stock
100
479
Open Market Acquisition
-
Exchange Announcement
-
May-11-2022
New Common Stock
100
493
Open Market Acquisition
-
Exchange Announcement
Gudaitis, Edward  (President, CEO & Director)
May-11-2022
New Common Stock
500
2,389
Open Market Acquisition
0.63
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Ihnatowycz, Ian Orest
Chairman of the Board
-
-

Gudaitis, Edward 
President, CEO & Director
905-817-8194
-
egudaitis@aceruspharma.com
Herschkowitz, Samuel 
Vice Chairman
-
-

Cotton, Geoffrey David
Independent Director
-
-

Gregory, Stephen Robert
Independent Director
-
-

Chabursky, Borys 
Lead Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gudaitis, Edward 
President, CEO & Director
905-817-8194
-
egudaitis@aceruspharma.com
Manzoor, Naveed 
Interim Chief Financial Officer
-
-

Witty, Chris 
Investor Relations
(646) 438-9385
-
cwitty@darrowir.com
Savard, Philippe 
Senior VP, General Counsel & Corporate Secretary
-
-

Damstra, Gavin 
Senior Vice President of International Commercial
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
